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Abstract
Background: A recent in vitro study indicates that IGOB131, a novel seed extract of the traditional West
African food plant Irvingia gabonensis, favorably impacts adipogenesis through a variety of critical metabolic
pathways including PPAR gamma, leptin, adiponectin, and glycerol-3 phosphate dehydrogenase. This study
was therefore aimed at evaluating the effects of IGOB131, an extract of Irvingia gabonensis, on body weight
and associated metabolic parameters in overweight human volunteers.
Methods: The study participants comprised of 102 healthy, overweight and/or obese volunteers (defined
as BMI > 25 kg/m2) randomly divided into two groups. The groups received on a daily basis, either 150 mg
of IGOB131 or matching placebo in a double blinded fashion, 30–60 minutes before lunch and dinner. At
baseline, 4, 8 and 10 weeks of the study, subjects were evaluated for changes in anthropometrics and
metabolic parameters to include fasting lipids, blood glucose, C-reactive protein, adiponectin, and leptin.
Results: Significant improvements in body weight, body fat, and waist circumference as well as plasma
total cholesterol, LDL cholesterol, blood glucose, C-reactive protein, adiponectin and leptin levels were
observed in the IGOB131 group compared with the placebo group.
Conclusion: Irvingia gabonensis administered 150 mg twice daily before meals to overweight and/or obese
human volunteers favorably impacts body weight and a variety of parameters characteristic of the
metabolic syndrome. This is the first double blind randomized placebo controlled clinical trial regarding
the anti-obesity and lipid profile modulating effects of an Irvingia gabonensis extract. The positive clinical
results, together with our previously published mechanisms of gene expression modulation related to key
metabolic pathways in lipid metabolism, provide impetus for much larger clinical studies. Irvingia gabonensis
extract may prove to be a useful tool in dealing with the emerging global epidemics of obesity,
hyperlipidemia, insulin resistance, and their co-morbid conditions.
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Background
Excess adipose tissue increases the workload of the cardi-
ovascular system, adversely alters immune function, and
dramatically increases the risk of heart disease, non-insu-
lin-dependent diabetes mellitus, obstructive pulmonary
disease, arthritis and a variety of cancers [1]. Although
once considered a major health problem isolated to devel-
oped countries, obesity is now recognized as a global
problem with potentially catastrophic consequences for
health economics. In Cameroon, for example, the
reported incidence of obesity in urban areas ranges from
17–21% [2]. This dramatic change reflects the social,
nutritional, and lifestyle changes involved in rural-urban
migration and the urbanization of rural areas. Worthy of
note in this context are the changes from traditional high
fibre diets and high-activity lifestyles to diets rich in satu-
rated fat and low in fibre, further compounded by reduc-
tion in physical activity levels [3,4]. Insulin resistance,
caused by the concomitant, complex interaction of envi-
ronment (e.g. diet, activity level, elevated body mass,
excess visceral adiposity) and genetic factors, is a funda-
mental pathophysiologic cause of the metabolic syn-
drome, a recognized risk factor for cardiovascular disease
[5,6]. Like many other obesity-related conditions, the
incidence of the metabolic syndrome is also on the rise in
Cameroon [7].
Nutritional management, especially caloric restriction for
the purpose of weight reduction, can improve insulin
action on target tissues like skeletal muscle, hepatocytes,
and peripheral and visceral adipocytes [8,9].
The consumption of Irvingia gabonensis, a fleshy West Afri-
can fruit, is common in traditional Nigerian and Cam-
eroonian cuisine. Initial observations suggested beneficial
changes in metabolic parameters were associated with the
high fiber content of Irvingia gabonensis [10]. Results of
subsequent analysis suggested that the earlier observa-
tions of the beneficial effects of Irvingia gabonensis could
not be accounted for by fiber content alone [11]. A recent
in vitro study using a validated experimental model
(murine 3T3-L1 adipocytes) provides compelling data
that Irvingia gabonensis seed extract may inhibit adipogen-
esis through modulation of PPAR gamma and glycerol-3
phosphate dehydrogenase in addition to beneficial
impact upon leptin and adiponectin [12].
The current clinical study was designed to evaluate if the
in vitro data could translate into in vivo clinical efficacy in
overweight and/or obese human volunteers.
Participants and methods
Study population
Participants for the study were recruited from the city of
Yaoundé, Cameroon and surrounding metro region
through radio and print media advertisement. Inclusion
criteria for study participation mandated: (1) men and
women ages 19 to 50 years, in general good health free
from significant medical illness that, in the opinion of the
investigator, could adversely compromise study participa-
tion for any reason; (2) stable body weight (+/- 2 kg) for
at least three months prior to study randomization with-
out use of medication known or suspected to affect body
weight or appetite; (3) no concomitant or recent (within
the past three months) bacterial or seasonal viral infection
(e.g. influenza); (4) BMI between 26 kg/m2 and 40 kg/m2;
(5) no attempts at weight loss through dietary interven-
tion over the three months prior to trial randomization;
(6) no participation in a structured weight control pro-
gram for at least three months prior to study randomiza-
tion; (7) non-smoker; (8) non-drinkers of sugary fizzy
drinks; (9) capability and willingness for multiple blood
sampling procedures; and (10) ability to competently
understand and sign the consent form.
Based on the above criteria, 120 consenting volunteers
(62 males and 58 females) were selected to participate in
the study. The protocol used was approved by the Cam-
eroon National Ethics Committee; the study was con-
ducted in accord with the Helsinki Declaration (1983
version).
Study design/intervention
The study was a randomized, double-blind, placebo-con-
trolled design for 10 weeks. The volunteers were ran-
domly divided into two groups – placebo or IGOB131.
The participants consumed either one capsule of placebo
or one capsule of IGOB131 (containing 150 mg of Irvingia
gabonensis extract) 30–60 minutes before lunch and din-
ner (BID) throughout the study period.
Test materials
All test materials were supplied by Gateway Health Alli-
ances, Inc. (Fairfield, CA, USA) in individual packets of
capsules. The identical-looking placebo and active formu-
lation capsules contained, respectively, maize-based pow-
der consisting of 150 mg maltodextrin, or 150 mg
IGOB131.
Anthropometric measurements
Height was measured with a locally manufactured wall-
mounted stadiometer, which was calibrated against the
Cameroon's Department of National Security identifica-
tion scale. Body weight and percent body fat, were
assessed using a Tanita™ BC-418 Segmental Body Compo-
sition Analyzer/Scale that uses bio-electrical impedance
analysis for body composition analysis. Body mass index
(BMI) was calculated using the weight and height meas-
urements. Waist circumference measurements to the near-
est 0.1 cm were taken at the mid-point between theLipids in Health and Disease 2009, 8:7 http://www.lipidworld.com/content/8/1/7
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bottom rib and the hip bone, without restrictive garments
using a flexible non expandable tape measure.
Dietary Intake
Three days before the collection of baseline measure-
ments and three times during the trial, dietary intake of
subjects was evaluated by a qualified dietician. Energy and
protein intakes were calculated using standard food com-
position tables based upon the 3-day food intake record.
No major dietary intervention or formal physical activity
program was instituted during the course of the study;
participants were instructed to maintain the current level
of physical activity prior to study randomization during
the course of the study.
Sample collection
Fasting blood samples (5 ml of blood) were collected at
baseline, and at 4, 8, and 10 weeks. Serum obtained from
each blood sample was split into multiple 500 μl aliquots
and stored at -20°C until needed for the measurement of
total cholesterol, LDL cholesterol, fasting blood glucose,
C-reactive protein, adiponectin, and leptin levels.
Analytical methods
Determination of glucose in blood using glucose oxidase
with an alternative oxygen receptor was adopted for this
study [13]. Serum total cholesterol was assayed by the
cholesterol oxidase method [14] while triglycerides as
well as serum glucose levels were assayed following the
method described by Buccolo & David [15]. Quantitative
determinations of C-reactive protein (CRP) was assessed
using a high sensitivity immunoassay (Oxis International,
Foster City, CA. USA) while serum leptin was determined
in duplicate using an enzyme-linked immunosorbent
assay (ELISA) (Diagnostic Systems Laboratory, Webster,
TX. USA) technique within the same assay, with an intra-
assay variance of 3.2%. Serum adiponectin was measured
in duplicate using an enzyme immunoassay (APLCO
Diagnostics, Salem, NH. USA) within the same assay.
Intra-assay variance was ≤ 5%.
Statistical analysis
Statistical analyses (Student's t-test and ANOVA) were per-
formed using the Statistical Package for the Social Sciences
(SPSS) software. Graphical representations of relative
changes in measured variables were performed using
Sigma Plot statistical package.
Results
The 120 volunteers (mean age 34, range 19–50) were
divided into 2 groups, with 60 randomly assigned to pla-
cebo and 60 to IGOB131 (active). Of these initial 120 vol-
unteers, 102 completed the 10 week study; 50 from the
placebo group, and 52 from the IGOB131 group. Eighteen
volunteers [placebo (n = 12) and IGOB131 (n = 6)]
dropped out of the study for the following reasons – not
experiencing rapid weight loss (n = 10); influenza attack
(n = 3); dryness of mouth (n = 3); no reason given (n = 2).
Food Intake
The mean daily energy intake in the IGOB131 group was
2767 ± 187 kcal of which 56% was from carbohydrate,
29% from protein, and 15% from fat. In the placebo
group, the mean daily energy intake was 3156 ± 185 kcal
of which 56% was from carbohydrate, 29% was from pro-
tein, and 15% was from fat. Seven-day dietary and activity
assessment of the subjects at baseline showed similar food
intake habits and energy levels.
Body weight, waist size and body fat
Baseline characteristics of the two groups were well-
matched and without significant differences at baseline
(Table 1). There were no significant differences in the
baseline body weight, waist circumference and serum lep-
tin measurements between the placebo and experimental
group (Table 1). However, by the tenth week, significant
differences were observed between the placebo and exper-
imental intervention groups, respectively, for body weight
(95.7 kg vs. 85.1 kg, respectively, p < 0.01), waist circum-
ference (101.1 cm vs. 88.1 cm, respectively, p < 0.05).
Body fat decreased over time in both groups but the exper-
imental group lost significantly more body fat (6.3%, p <
0.05) compared to the placebo group (1.9%) (Table 1).
When corrected for placebo response, the pattern of rela-
tive changes in weight and waist circumference was found
to be different between the two groups, consistent with a
difference in response to the intake of the extract (Figure
1).
Total and LDL cholesterol, C-reactive proteins, leptin
These variables decreased from baseline, though at differ-
ent rates and magnitudes associated with duration of the
study, with the experimental group showing statistically
significant changes compared with the placebo group at
week-10 (Table 1).
While baseline levels of serum lipids were similar in the
two groups, significant differences were observed between
the two as the study progressed with the experimental
group showing progressively greater improvement. At
week-10, significant differences were observed for total
cholesterol (placebo: 142.5 mg/dl vs. IGOB131: 111.9
mg/dl, p < 0.05) and LDL cholesterol (placebo: 77.7 mg/
dl vs IGO131: 59.77 mg/dl, p < 0.01). Compared to base-
line values, total cholesterol decreased by 1.9% in the pla-
cebo group as opposed to 26.2% for the IGOB131 group
while LDL cholesterol levels fell by 4.8% in the placebo
compared to 27.3% in the IGOB131 group. Correcting forLipids in Health and Disease 2009, 8:7 http://www.lipidworld.com/content/8/1/7
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placebo values, the relative change in the total cholesterol
and LDL cholesterol was observed to follow a similar pat-
tern (Figure 2) in the experimental group, suggesting a
similar response mechanism to IGOB131 intake.
Like in the case of the other parameters measured, C-reac-
tive protein and leptin levels decreased over time in both
groups. The rate of decrease was however accelerated in
the IGOB131 relative to the placebo-group. Serum levels
of CRP fell by 1.2% in the placebo group as opposed to
52.0% in the experimental group relative to baseline. On
the other hand, leptin levels decreased by 9.3% in the pla-
cebo group compared to a 48.6% in the IGOB131 group
over the 10-week experimental period.
Fasting blood glucose levels
Blood glucose levels in the experimental group (85.6 mg/
dl ± 5.6 mg/dl) and in the placebo group (81.4 ± 9.6 mg/
dl) were similar at baseline but decreased to significantly
different levels (P < 0.05) at week-10 of the study (Table
1). In relative terms, decreases in placebo and treatment
groups were 5.3% vs. 22.5%, respectively (Figure 3). Cor-
rected for the placebo values, the changes in blood glu-
cose levels were similar to that of lipids (Figure 2).
Adiponectin levels
Baseline serum adiponectin levels were comparable
between the two groups (placebo: 12.1 mg/l ± 3.21 mg/l;
IGOB131: 12.16 mg/l ± 3.04 mg/l), but increased with
time (Table 1). By week-10 of the study adiponectin levels
in the placebo group increased by 23.4% compared to
159.8% in the experimental group. Corrected for placebo
values, the rate of increase in serum adiponectin levels in
IGOB131 group followed an exponential curve (Figure 4).
Adverse events
Treatment of overweight and obese subjects with
IGOB131 was well-tolerated. Adverse events with an inci-
dence >n = 3 included headache (n = 5), sleep difficulty (n
= 6), and intestinal flatulence (n = 6). The incidence of all
reported side effects was similar in the placebo group as
well as in the treatment group.
Table 1: Changes* in body weight, waist, leptin, fat, total cholesterol, LDL cholesterol, glucose and adiponectin measurements in the 
course of the study.
Time (weeks)
Variables Group Base line 4 8 10 Over change
Weight (Kg) Placebo 96.4 ± 12.3 95.8 ± 8.2 95.1 ± 10.6 95.7 ± 15.2 -0.7
IGOB131 97.9 ± 9.1 94.3 ± 5.5 a 89.7 ± 4.7 a 85.1 ± 3.1b -12.8
Waist (cm) Placebo 106.4 ± 10.8 102.7 ± 10.6 101.1 ± 14.8 101.1 ± 15.8b -5.3
IGOB131 105.1 ± 6.3 98.0 ± 8.4a 90.1 ± 8.70a 88.1 ± 7.6 -16.19
Leptin (ng/ml) Placebo 31.3 ± 1.8 29.4 ± 1.4 28.1 ± 1.8 28.4 ± 1.8 -2.9
IGOB131 32.9 ± 1.6 18.1 ± 1.3a 16.8 ± 1.2a 16.9 ± 1.3b -16.0
Fat (%) Placebo 34.7 ± 8.6 33.31 ± 10.9 32.9 ± 11.9 32.7 ± 15.7 -1.99
IGOB131 34.2 ± 7.9 31.6 ± 5.4a 28.2 ± 6.6a 27.9 ± 5.5a -6.3
LDL cholesterol (mg/dL) Placebo 77.4 ± 9.2 76.5 ± 8.9 74.1 ± 9.3 73.7 ± 8.3 -3.75
IGOB131 82.2 ± 8.1 71.8 ± 5.9b 64.7 ± 8.9b 59.8 ± 5.0b -22.44
Total cholesterol (mg/dL) Placebo 145.2 ± 22.4 143.9 ± 12.2 142.1 ± 13.6 142.4 ± 12.1 -2.8
IGOB131 151.7 ± 18.5 133.7 ± 16.6a 120.1 ± 11.9 a 111.9 ± 5.8a -39.8
C-reactive protein (mg/L) Placebo 1.46 ± 0.05 1.46 ± 0.04 1.445 ± 0.03 1.455 ± 0.05 -0.01
IGOB131 1.49 ± 0.041 0.91 ± 0.05a 0.71 ± 0.04b 0.72 ± 0.05b -0.78
Glucose (mg/dL) Placebo 81.4 ± 9.6 79.5 ± 10.1 77.8 ± 9.4 77.1 ± 7.8 -4.3
IGOB131 85.55 ± 5.59 76.6 ± 10.3a 68.7 ± 9.3a 66.3 ± 4.9a -19.3
Adiponectin (mg/L) Placebo 12.1 ± 3.2 15.2 ± 3.5 14.6 ± 3.5 14.94 ± 3.9 + 2.8
IGOB131 12.2 ± 3.0 24.8 ± 3.8a 31.0 ± 4.0b 31.6 ± 3.9a + 19.4
a P < 0.05; b P < 0.01 compared with PlaceboLipids in Health and Disease 2009, 8:7 http://www.lipidworld.com/content/8/1/7
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Discussion
The present study suggests that IGOB131, a seed extract of
Irvingia gabonensis, safely and significantly reduces body
weight in overweight and/or obese subjects, and has a
favorable impact upon a variety of other metabolic
parameters. The current clinical study shows IGOB131
administration is associated with increases in plasma adi-
ponectin levels and decreases in leptin and CRP levels in
comparison with the placebo group. These observations
support the results of a recent in vitro study [12] which
suggests a favorable impact upon adipogenesis associated
with IGOB131.
Insulin resistance is the hallmark of the metabolic syn-
drome and is strongly associated with excess adiposity
[16]. A variety of adipocyte-derived biologically active
molecules have been identified, including leptin, resistin,
TNF-α, and IL-6, that may contribute to obesity-linked
metabolic abnormalities [17]. Since plasma leptin levels
are closely correlated with the level of adipose tissue [18],
the decreases in plasma leptin level associated with
IGOB131 treatment may be attributable to the decrease of
adipose tissue induced as a consequence of weight loss.
According to McTernan et al. [17], adipose tissue plays a
prominent role in the clinical expression of metabolic
syndrome, most likely mediated by the increased release
and peripheral tissue action of non-esterified fatty acids
and by the dysregulated production of adipocyte-secreted
proteins, including leptin, adiponectin, resistin, TNF-α,
and IL-6. Adiponectin, known to correlate with endothe-
lial function and vascular health, is exclusively expressed
in adipose tissue and abundant in human plasma, and
appears to be decreased in individuals with obesity and
type 2 diabetes, risk factors for atherosclerosis[19].
The observation of a significant weight loss, as well as an
increase in adiponectin is consistent with earlier reports in
the literature observing an association between weight
loss and an increase in adiponectin levels [20].
IGOB131 is relatively rich in plant-derived protein and
antioxidants. A study by Baum et al, [21] had earlier
shown a reduction of both total cholesterol and triglycer-
ides levels in a hypercholesterolemic man who was fed a
plant protein diet. Other studies have shown metabolic
syndrome-preventive activity of antioxidant components
(e.g. vitamin C, polyphenols). A number of polyphenols
such as epigallocatechin gallate have anti-obesity activity
and may improve metabolic disorders via modulation of
adipokines and growth factors, including metabolic
improvement of leptin function [22-24]. Although the
active principles of IGOB131 have not yet been fully iden-
tified, it is possible that it contains some of the above
mentioned compounds.
In conclusion, Irvingia gabonensis extract administered
twice a day to healthy, overweight and obese individuals
resulted in both weight reduction (body weight, body fat,
waist size) and an improvement in metabolic parameters
associated with insulin resistance. The current results sug-
gest that IGOB131 may be a helpful adjunct in the man-
agement of overweight and/or obesity, supporting
previous suggestions from our laboratory [25].
Changes in body weight and waist circumference measure- ments in IGOB131 group corrected for placebo values Figure 1
Changes in body weight and waist circumference 
measurements in IGOB131 group corrected for pla-
cebo values.
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Changes in measured characteristics in IGOB131 group cor- rected for placebo values Figure 2
Changes in measured characteristics in IGOB131 
group corrected for placebo values.
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Percentage decrease in body weight (WT), Waist size (WS), Fat (FAT), Total Cholesterol (TCHOL), LDL cholesterol (LDL),  Glucose (GLU), Leptin (LEP), C-reactive protein (CRP) and Adiponectin (ADIP) after 10 weeks of use of extract IGO131 Figure 3
Percentage decrease in body weight (WT), Waist size (WS), Fat (FAT), Total Cholesterol (TCHOL), LDL 
cholesterol (LDL), Glucose (GLU), Leptin (LEP), C-reactive protein (CRP) and Adiponectin (ADIP) after 10 
weeks of use of extract IGO131.
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Changes in the adiponectin levels in IGOB131 group corrected for placebo Figure 4
Changes in the adiponectin levels in IGOB131 group corrected for placebo.
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